Targeting XPO6 Inhibits Prostate Cancer Progression and Enhances the Suppressive Efficacy of Docetaxel

Investigators detected the expression level of XPO6 in prostate cancer tissues by immunohistochemistry and analyzed the correlation between clinicopathological characteristics and XPO6 level based on TCGA database.